Evaluating Biological Effects of Sirolimus-Eluting Cardiovascular Stents

The aim of the investigation was to study the influence of the sirolimus-eluting cardiovascular stents on hematological and biochemical blood parameters in vitro.

Materials and Methods. Angioplasty of aorta-iliac segment of the femoral artery was performed to six rabbits with implantation of MS 2.5×11 mm bare metal Cobalt-Chromium stents and stents of the same model developed by NanoMed (Russia) with linear-chain carbon and drug-eluting coatings (2 μg/mm² of sirolimus) to other six rabbits. Animal condition was assessed visually and by hematological and biochemical blood parameters 1, 2, 4, and 7 weeks after implantation compared to the rabbits of intact and control groups.

Results. Application of the stents with linear-chain carbon and drug-eluting coatings reduces the risk of restenosis. Gradual destruction of the polymeric coating provides local dosed release of the drug substance in the area of the stented vessel wall, inhibiting thereby the neointimal hyperplasia. Implantation of sirolimus-eluting stents did not cause significant changes in biochemical and hematological blood parameters of rabbits in comparison with bare metal stents. Changes in the blood tests of the control animals compared to the intact ones are likely to be the result of surgical intervention. This fact allows us to pass over to the clinical trials of sirolimus-eluting coronary stents.

1. Karpov Yu.A., Samko A.N., Buza V.V. Koronarnaya angioplastika i stentirovanie [Coronary angioplasty and stenting]. Moscow: MIA; 2010.
2. Fedorchenko A.N. Restenoz kak osnovnaya problema posle chreskozhnykh koronarnykh vmeshatel’stv. Avtoref. dis. … dokt. med. nauk [Restenosis as the main problem following percutaneous coronary interventions. DSc Thesis]. Novosibirsk; 2009.
3. Bokeriya L.A., Alekyan B.G., Golukhova E.Z., Buziashvili Yu.I., Nikitina T.G., Staferov A.V., Zakaryan N.V. Application of stents with antiproliferative drug-eluting coatings in managing patients with ischemic heart disease. Kreativnaya kardiologiya 2007; 1–2: 183–199.
4. Bokeriya L.A., Alekyan B.G., Zakaryan N.V., Staferov A.V. Koronarnoe stentirovanie: sovremennoe sostoyanie voprosa. V kn.: Rukovodstvo po rentgenoendovaskulyarnoy khirurgii serdtsa i sosudov. T. 3 [Coronary stents: current status. In: Texbook of endovascular surgery for cardiovascular diseases]. Pod red. Bokeriya L.A., Alekyana B.G., Anri M. [Bokeriya L.A., Alekyan B.G., Anri M. (editors)]. Moscow; 2008; p. 232–260.
5. Li Ch.Kh., Serruyz P.U. Stents with drug-eluting coatings. Mezhdunarodnyy zhurnal interventsionnoy kardioangiologii 2003; 1: 9–18.
6. Adamyan A.A. Main directions and perspectives in creation and clinical application of polymer implants. Biosovmestimost’ 1994; 2: 97–107.
7. Sevast’yanov V.I., Kirpichnikov M.P. Biosovmestimye materialy [Biocompatible materials]. Moscow: MIA; 2011; 544 p.
8. Yin R.-X., Yang D.-Z., Wu J.-Z. Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis. Theranostics 2014; 4(2): 175–200, https://doi.org/10.7150/thno.7210.
9. Ielasi A., Latib A., Colombo A. Current and future drug-eluting coronary stent technology. Expert Rev Cardiovasc Ther 2011; 9(4): 485–503, https://doi.org/10.1586/erc.11.5.
10. Lyubchenko O.D., Kruchinina A.D., Shatrov A.N. Kinetics of degradation of antiproliferative polymer coating of stents in vitro. Izvestiya vysshikh uchebnykh zavedeniy. Povolzhskiy region. Estestvennye nauki 2015; 2(10): 55–61.
11. McPherson R.A., Pincus M.R. Henry’s clinical diagnosis and management by laboratory methods: 22nd edition. Elsevier Saunders, Philadelphia; 2011.

Kruchinina А.D., Lyubchenko О.D., Yastremskaya Y.P., Shatrov А.N. Evaluating Biological Effects of Sirolimus-Eluting Cardiovascular Stents. Sovremennye tehnologii v medicine 2017; 9(1): 56, https://doi.org/10.17691/stm2017.9.1.06